- Home
- BST vs SLBT Comparison
BST vs SLBT Comparison
Compare BST & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BST | SLBT |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BST | SLBT |
|---|---|---|
| Price | $49.70 | $2.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 84.0K | 72.2K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.87 | $2.54 |
| 52 Week High | $51.30 | $6.25 |
Technical Indicators
Market Signals| Indicator | BST | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 40.10 |
| Support Level | $44.24 | $2.54 |
| Resistance Level | $50.80 | $3.40 |
| Average True Range (ATR) | 0.78 | 0.17 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 73.96 | 0.00 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.